Navigation Links
Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research
Date:4/17/2008

PALO ALTO, Calif., April 17 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK), a biopharmaceutical company focused on discovering and developing drugs to treat serious diseases, today announced that it made four preclinical data presentations at the 99th Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, Calif. The abstracts highlighted results from Telik's Research and Development programs.

Identification and Characterization of Novel Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor 2 [Abstract # 1439]

Inhibition of the vascular endothelial growth factor receptor signaling

pathway with antibodies or small molecules has been proven effective as an

anti-cancer therapy. Through the use of Telik's Target-Related Affinity

Profiling (TRAP(R)) screening technology, novel inhibitors of VEGFR2

kinase were discovered. The inhibitors belong to nine structural classes,

among which E2B8 and EAAF are sub-micromolar inhibitors of the kinase.

Mechanism of Induction of Apoptosis by TLK199 (TELINTRA(R)) in Human Leukemia Cell Lines [Abstract # 2270]

Telik researchers conducted studies with data highlighting TLK199, a novel

glutathione analog inhibitor of the enzyme glutathione S-transferase P1-1,

which induces apoptosis, or programmed cell death, in human HL60

promyelocytic cells and TF-1 erythroleukemic cells. Treatment of the

leukemia cells with TLK199 also resulted in an increase of the

phosphorylation of eIF2alpha, a key signaling event in the integrated

stress response (ISR), and in induction of multiple genes implicated in

ISR. Telik currently has ongoing studies of TLK199 in clinical

development for the treatment of myelodysplastic syndrome (MDS).

Identification of a Novel Class of Nonpeptidyl Small-Molecule Inhibitors of the Human Proteasome [Abstract # 3271]

The ubiquitin-proteasome system (UPS) mediated protein turnover underlies

many signaling pathways that are fundamental to cell proliferation,

survival and death. Many important cellular proteins that are

dysregulated in cancer are proteasome substrates. Telik researchers have

identified multiple nonpeptidyl small-molecule hits that inhibited human

proteasome activity both biochemically and in cells. The best series

exhibited many desirable features including excellent cellular specificity,

equal activity against all three proteolytic sites of the proteasome, and

potent and broad anti-tumor activity in vitro.

Target-Related Affinity Profiling (TRAP(R)): Efficient Cancer Drug Discovery at Telik [Abstract # 4754]

Compounds for these preclinical studies came through the use of Telik's

TRAP technology, which provides an alternative screening method that is

based on a unique molecular descriptor called an affinity fingerprint. An

affinity fingerprint is based on the binding energy of small molecules to

proteins. Advanced computational methods are used to determine affinity

fingerprints, and to select compounds for screening. Advantages to using

TRAP include: a "low throughput" approach using complex, physiologically

relevant assays; identification of small molecule drug leads after testing

as few as 200 compounds; high level of success against a wide range of

cancer targets; enables scaffold hopping; and can speed the optimization

of small molecule drugs.

Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates.

TELIK, the Telik logo, TELCYTA, TELINTRA and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Telik Announces Fourth Quarter and 2007 Year End Financial Results and 2008 Guidance
2. Telik Announces Revised Date for Year-End Financial Release, Conference Call and Webcast
3. Telik Announces Year-End Financial Release, Conference Call and Webcast
4. Telik Announces Presentation and Webcast at JPMorgan Healthcare Conference
5. Telik Announces Presentation and Webcast at UBS Global Life Sciences Conference
6. Telik Announces Presentation and Webcast at Bear Stearns Healthcare Conference
7. ProMetic presents preclinical data for prostate and pancreatic cancer at the AACR Meeting
8. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect
9. Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR
10. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
11. SGX Presents Preclinical MET Data at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... UK (PRWEB) , ... December 08, 2016 , ... ... precision light to control cells — optogenetics — is key to exciting advances ... of the art, spatially patterned light projected via free-space optics stimulates small, transparent ...
(Date:12/8/2016)... ... December 08, 2016 , ... KBioBox llc ... to client demand KbioBox developed a sophisticated “3 click” gene dditing off target ... from KBioBox’s new website, https://www.kbiobox.com/ and powered by the company’s ...
(Date:12/8/2016)... N.J. , Dec. 8, 2016 Soligenix, ... biopharmaceutical company focused on developing and commercializing products to ... need, announced today that it will be hosting an ... am ET on the origins of innate defense regulators ... a review of oral mucositis and the recently announced ...
(Date:12/8/2016)... , Dec. 8, 2016   Biocept, ... leading commercial provider of clinically actionable liquid biopsy ... announces that clinical data featuring its Target Selector™ ... tissue biopsy for the detection of actionable biomarkers ... from research sponsored by Sara Cannon Research Institute ...
Breaking Biology Technology:
(Date:11/21/2016)... VILNIUS, Lithuania , Nov. 21, 2016 /PRNewswire/ ... identification and object recognition technologies, today announced that ... for smart cards was submitted for the ... and successfully passed all the mandatory steps of ... III evaluation is a continuing test of fingerprint ...
(Date:11/16/2016)... Nov. 16, 2016 Sensory Inc ., ... security for consumer electronics, and VeriTran , ... retail industry, today announced a global partnership that ... to authenticate users of mobile banking and mobile ... software which requires no specialized biometric scanners, ...
(Date:11/14/2016)... 14, 2016  Based on its recent ... & Sullivan recognizes FST Biometrics with the ... Visionary Innovation Leadership. FST Biometrics emerged as ... market by pioneering In Motion Identification (IMID) ... seamless, and non-invasive verification. This patented solution ...
Breaking Biology News(10 mins):